

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6988971

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	PAM TSURUDA	05/30/2019
	JILL HOPKINS	09/13/2018
	HARRY SWEIGARD	05/31/2019
	YAN POON	05/31/2019
	JAMIE DANANBERG	06/04/2019
	DANIEL MARQUESS	06/04/2019
	NATHANIEL DAVID	05/31/2019
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	UNITY BIOTECHNOLOGY, INC.	
<b>Street Address:</b>	285 EAST GRAND AVE.	
<b>City:</b>	SOUTH SAN FRANCISCO	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	94080	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	17412003
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(650) 327-3400	
<b>Email:</b>	phillips@bozpat.com	
<b>Correspondent Name:</b>	BOZICEVIC, FIELD & FRANCIS LLP	
<b>Address Line 1:</b>	201 REDWOOD SHORES PKWY	
<b>Address Line 2:</b>	SUITE 200	
<b>Address Line 4:</b>	REDWOOD CITY, CALIFORNIA 94065	
<b>ATTORNEY DOCKET NUMBER:</b>	UNITY-001DIV2	
<b>NAME OF SUBMITTER:</b>	RUDY J. NG	
<b>SIGNATURE:</b>	/Rudy J. Ng, Reg. No. 56,741/	
<b>DATE SIGNED:</b>	10/26/2021	

PATENT

**Total Attachments: 7**

source=UNITY-001CON - UNITY executed assignment#page1.tif

source=UNITY-001CON - UNITY executed assignment#page2.tif

source=UNITY-001CON - UNITY executed assignment#page3.tif

source=UNITY-001CON - UNITY executed assignment#page4.tif

source=UNITY-001CON - UNITY executed assignment#page5.tif

source=UNITY-001CON - UNITY executed assignment#page6.tif

source=UNITY-001CON - UNITY executed assignment#page7.tif

## CONFIRMATORY ASSIGNMENT

WHEREAS, the undersigned:

1. Pam Tsuruda 3280 Bayshore Boulevard Brisbane, CA 94005	2. Jill Hopkins 3280 Bayshore Boulevard Brisbane, CA 94005
3. Harry Sweigard 3280 Bayshore Boulevard Brisbane, CA 94005	4. Yan Poon 3280 Bayshore Boulevard Brisbane, CA 94005
5. Jamie Dananberg 3280 Bayshore Boulevard Brisbane, CA 94005	6. Daniel Marquess 3280 Bayshore Boulevard Brisbane, CA 94005
7. Nathaniel David 3280 Bayshore Boulevard Brisbane, CA 94005	

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in  
**Technology to Inhibit Progression of Neovascularization and Vaso-Obliteration**

for which application serial number 16/160,840 was filed on October 15, 2018 in the United States Patent and Trademark Office;

WHEREAS, Unity Biotechnology, Inc., a corporation of the State of Delaware, having a place of business at 3280 Bayshore Blvd, Brisbane, California 94005 in the United States of America, (hereinafter "Assignee"), is desirous of acquiring and confirming that it has acquired the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)") and the entire right to claim priority from each Application.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do/does hereby sell, assign, quitclaim, transfer and convey, and confirm that said Inventor(s) have sold, assigned, quitclaimed, transferred, and conveyed unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Application(s), including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to

each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.


4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:


Date: 30 MAY 2019

  
Pam Tsuruda


Date: \_\_\_\_\_

\_\_\_\_\_  
Jill Hopkins


Date: 5/31/2019

  
Harry Sweigard

Date: 5/31/2019

  
Yan Poon


Date: 04 Jun 2019

  
Jamie Dananberg

Date: 04 Jun 2019


  
Daniel Marquess

Date: 5/31/19

  
Nathaniel David

RECEIVED AND AGREED TO BY ASSIGNEE:  
Unity Biotechnology, Inc.

Date: 6/12/19

Signature: 

Name: **Tamara L. Tompkins**

Title: **GC and Corporate Secretary**

CONFIRMATORY ASSIGNMENT

WHEREAS, the undersigned:

Jill Hopkins, 3280 Bayshore Boulevard, Brisbane, California 94005 US  
Pam Tsuruda, 3280 Bayshore Boulevard, Brisbane, California 94005 US  
Claude Chapman, 3280 Bayshore Boulevard, Brisbane, California 94005 US  
Harry Sweigard, 3280 Bayshore Boulevard, Brisbane, California 94005 US  
Yan Poon, 3280 Bayshore Boulevard, Brisbane, California 94005 US  
Daniel Marquess, 3280 Bayshore Boulevard, Brisbane, California 94005 US  
Nathaniel David, 3280 Bayshore Boulevard, Brisbane, California 94005 US  
Jamie Dananberg, 3280 Bayshore Boulevard, Brisbane, California 94005 US

hereinafter "Inventor(s)", have invented certain new and useful improvements in "Treatment of Ophthalmic Conditions Such as Macular Degeneration, Glaucoma, and Diabetic Retinopathy Using Pharmaceutical Agents that Eliminate Senescent Cells"

for which a PCT application serial number PCT/US18/46553 was filed on August 13, 2018 in the U.S. Receiving Office of the Patent Cooperation Treaty.

WHEREAS, Unity Biotechnology, Inc., a corporation of the State of Delaware, having a place of business at 3280 Bayshore Blvd, Brisbane, California 94005 in the United States of America, (hereinafter "Assignee"), is desirous of acquiring and confirming that it has acquired the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)") and the entire right to claim priority from each Application.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do/does hereby sell, assign, quitclaim, transfer and convey, and confirm that said Inventor(s) have sold, assigned, quitclaimed, transferred, and conveyed unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Application(s), including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past,

present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.


4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 9/13/18

  
Jill Hopkins

Date: \_\_\_\_\_

\_\_\_\_\_  
Pam Tsuruda

Date: \_\_\_\_\_

\_\_\_\_\_  
Claude Chapman

Date: \_\_\_\_\_

\_\_\_\_\_  
Harry Sweigard

Date: \_\_\_\_\_

\_\_\_\_\_  
Yan Poon

Date: \_\_\_\_\_

\_\_\_\_\_  
Daniel Marquess

Date: \_\_\_\_\_

\_\_\_\_\_  
Nathaniel David


Date: \_\_\_\_\_

\_\_\_\_\_  
Jamie Dananberg



RECEIVED AND AGREED TO BY ASSIGNEE:  
Unity Biotechnology, Inc.

Date: 6/12/19

Signature: 

Name:

Title:

Tamara L. Tompkins  
GC and Corporate Secretary